Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC50s of 2.7 and 4.5nm for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis. Antineoplastic, anti-inflammatory and immunomodulating agent. Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Synonyms: (b-R)-b-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile, INCB018424, INC18424, NCB018424, NCB18424 CAS No: 941678-49-5 Molecular Formula: C17H18N6 Molecular Weight: 306.37 Appearance: White to off-white powder Purity: 98% (HPLC, TLC) Solubility: Souble in DMSO at 28mg/ml. Soluble in ethanol at 15mg/ml with warming, very poorly soluble in water, maximum solubility in plain water is estimated to be about 25-50uM, buffers, serum or other additives may increase or decrease the aqueous solubility. Storage and Stability: Powder may be stored at -20C. Stable for 6 months after receipt at -20C. Reconstitute with DMSO or EtOH. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Light sensitive.
Molekulargewicht:
306.37
Reinheit:
98% (HPLC, TLC)
Formulierung:
White to off-white powder
CAS Nummer:
[941678-49-5]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
